Vigil Neuroscience (VIGL)
(Delayed Data from NSDQ)
$4.40 USD
+0.21 (5.01%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $4.26 -0.14 (-3.18%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VIGL 4.40 +0.21(5.01%)
Will VIGL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIGL
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
VIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%
Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade
Other News for VIGL
Vigil Neuroscience price target raised by $1 at Wedbush, here's why
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Vigil Neuroscience Inc (VIGL) and Cooper Co (COO)
Vigil Neuroscience Inc.: A Cautious Sell Amid Development Uncertainties and Potential Conflict of Interest
Buy Rating Affirmed for Vigil Neuroscience Amid Promising Alzheimer’s Treatment Developments
Sanofi investing $400M in Vigil Neuroscience, says Guggenheim